Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BXCL501 for Agitation Associated With Dementia
NCT05665088Phase 3Terminated
- Sponsor
- BioXcel Therapeutics, Inc.
- Start
- Dec 2022
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dexmedetomidine in Dementia (3 arms), sponsored by BioXcel Therapeutics, Inc. Primary endpoint: PANSS Excitatory Component at 24 hours. Started Dec 2022; status: terminated.
02
Drugs
dexmedetomidine
03
Conditions
Dementia
Beyond the preview
Go deeper on NCT05665088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05665088.